MedTrace Logo

Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer

NCT00482716 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2014-01-10

No results posted yet for this study

Summary

RATIONALE: Epoetin alfa and epoetin beta may cause the body to make more red blood cells. Red blood cells contain iron that is needed to carry oxygen to the tissues. It is not yet known whether epoetin alfa or epoetin beta are more effective when given with or without iron infusion in treating anemia in patients with cancer.

PURPOSE: This randomized phase III trial is studying epoetin alfa or epoetin beta to compare how well they work with or without iron infusion in treating anemia in patients with cancer.

Conditions

  • Anemia
  • Leukemia
  • Lymphoma
  • Multiple Myeloma and Plasma Cell Neoplasm
  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

BIOLOGICAL

epoetin alfa

BIOLOGICAL

epoetin beta

DIETARY_SUPPLEMENT

iron dextran complex

DIETARY_SUPPLEMENT

iron sucrose injection

Sponsors & Collaborators

  • St. Bartholomew's Hospital

    lead OTHER

Principal Investigators

  • Samir G Agrawal, MD, PhD · St. Bartholomew's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00482716 on ClinicalTrials.gov